The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/ leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
 
Teresa Mercade Macarulla
No Relationships to Disclose
 
Jens T. Siveke
Consulting or Advisory Role - Baxalta; Celgene; Lilly; Merrimack
Research Funding - 4SC; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Novartis
Travel, Accommodations, Expenses - Celgene; Roche
 
Andrew Peter Dean
Honoraria - Specialised Therapeutics
Consulting or Advisory Role - Baxalta; Celgene
 
Richard Hubner
Honoraria - Abbott Nutrition; Ipsen
Consulting or Advisory Role - BTG; Shire
Travel, Accommodations, Expenses - Bayer; Celgene
 
Jean-Frédéric Blanc
Honoraria - Baxalta/Shire; Bayer Schering Pharma; Gilead Sciences
Consulting or Advisory Role - Baxalta/Shire; Bristol-Myers Squibb; Novartis; Onxeo
Travel, Accommodations, Expenses - Bayer Schering Pharma
 
David Cunningham
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Sanofi (Inst)
 
Li-Tzong Chen
Consulting or Advisory Role - Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; Merrimack; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; Syncope, Taiwan; TTY Biopharm
Research Funding - GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Polaris (Inst); TTY Biopharm (Inst)
Patents, Royalties, Other Intellectual Property - anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan
 
Beloo Mirakhur
Employment - Ipsen
Stock and Other Ownership Interests - GlaxoSmithKline; Ipsen
 
Jie Chen
Employment - Shire
Stock and Other Ownership Interests - Shire
 
Floris A de Jong
Employment - Shire
Stock and Other Ownership Interests - Amgen; Shire
 
Andrea Wang-Gillam
Consulting or Advisory Role - Merrimack; Newlink Genetics; pfizer
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); CTI (Inst); EMD Serono (Inst); Halozyme (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); OncoMed (Inst); pfizer (Inst); Plexxikon (Inst); Precision Therapeutics (Inst); Verastem (Inst)